9-[2-(Phosphonomethoxy)alkoxy]purines have been prepared and evaluated as antiviral agents. These compounds are the first reported acyclonucleotides in which an acyclic phosphonic acid-bearing substituent is attached to N-9 of a purine via a nitrogen-oxygen bond. Some 2-(phosphonomethoxy)ethoxy derivatives, e.g. (24), (25) and (27), have potent activity against herpesviruses. Some 3-hydroxy-2-(phospho-' nomethoxy)propoxy derivativ~s, e.g. (23) and (34), and a cyclic phosphonate (35), are potent and selective inhibitors ofthe replication of visna virus, a retrovirus. . 'For correspondence. Tel.(0737) 364183; Fax (0737) 364073. LQ L J~_.
Introduction
A considerable number of antiviral acyclic analogues of nucleosides and nucleotides have been reported in recent years. The most potent and selective antiviral acyclonucleo sides are all N-9-substituted derivatives of guanine, e.g. acyclovir (Elion et al., 1977; Schaeffer et al., 1978) , penciclovir (Harnden et et., 1987; Boyd et al., 1987) and buciclovir (Oberg and Johansson, 1984) , and are active only against members of the herpesvirus family which specify a virus-encoded thymidine kinase [TK+ strains of herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus CVZV) and Epstein-Barr virus (EBV)]. This is because the first stage in their intracellular activation involves conversion to a monophosphate in infected cells only by the viral TK (Elion et al., 1977; Larsson et al., 1986) . Subsequent phosphorylations by host cell enzymes result in formation of a triphosphate, which is an inhibitor of the viral DNA polymerase. Another acyclonucleoside, ganciclovir (Smee et aI., 1983) , is active against cytomegalovirus (CMV), which does not specify a TK, but this compound can be phosphorylated by mammalian cell enzymes and has proved to be more toxic (Collaborative DHPG Treatment Study Group, 1986) .
In contrast, the acyclonucleotides mimic monophosphate derivatives and have a much wider spectrum of activity against DNA viruses, including TK-strains of herpesviruses (De Clercq et et., 1986) . Some acyclonucleotides also inhibit the replication of retroviruses, including human immunodeficiency virus (HIV), the causative agent in acquired immunodeficiency syndrome (AIDS) (De Clercq et el., 1987; Pauwels et al., 1988) .
Antiviral acyclonucleotides include N-9-substituted derivatives of adenine, guanine and other purines, and also an N-1-substituted cytosine (De Clercq et al., 1987) . Thus, (S)-HPMPA exhibits broad-spectrum anti-DNA virus activity, PMEA and PMEDAP are active against HIV and (S)-HPMPC has selective activity against CMV. The selectivity of these compounds is dependent upon the ability of their diphosphate derivatives (triphosphate equivalents) to inhibit the viral polymerases at lower concentrations than are required for inhibition of host cell DNA polymerases (Votruba et sl., 1988; Merta et al., 1990; Balzarini et sl., 1991) .
We have recently reported synthetic routes to 9-alkoxypurine (Harnden et al., 1988 (Harnden et al., , 1990b ) and 1-alkoxypyrimidine (Harnden et al., 1990a) acyclonucleosides. Some 9-(hydroxyalkoxy)guanine derivatives also have potent and selective activity against TK+ strains of herpesviruses (Harnden et al., 1990b; Bailey et al., 1991) . In this publication we describe an extension of our previously developed synthetic methodology for preparation of analogous 9-[2-(phosphonomethoxy)alkoxy]purines and the activities of these new acyclonucleotides against herpesviruses and visna virus, a lentivirus closely related to HIV.
Results

Chemistry
Two synthetic routes were employed in the synthesis of 9-[2-(phosphonomethoxy)alkoxy]purines. The first of these involved the reaction of an alkoxyamine with a 4,6-dichloro-5-formamidopyrimidine and subsequent formation of the imidazole ring (Fig. 1 ). In the second, an alcohol was coupled with a 9-hydroxypurine under Mitsunobu conditions (Figs 2 and 3) .
Intermediate phosphonomethoxyalkanols and phosphonomethoxyalkoxyamines were prepared as shown ( Fig. 4) . Thus, treatment of 1,3-dioxolane (1) with acetyl bromide, followed by reaction with triethyl phosphite, (2), which on acid hydrolysis gave the alcohol (3)in 70% yield. Elaboration to the alkoxyamine (4) via the phthalimide was achieved as described previously (Harnden et al., 1990b) in 64% overall yield from (3). Synthesis of the branched chain compounds (8 and 9) commenced from 1,3-dibenzyloxy-2-hydroxy-propane (5) . Reaction with paraformaldehyde and hydrogen chloride gas in dry dichloromethane afforded a chloromethoxy derivative, which was immediately reacted with triethylphosphite to afford the protected phosphonomethoxy compound (6) in 51% overall yield. Hydrogenolysis then yielded the diol (7)in 30% yield, which was converted to 71% yield to a monacetate (8)using trimethyl orthoacetate followed by acid hydrolysis. The alkoxyamine (9) was obtained in 65% overall yield from (8)via the phthalimide derivative.
Reaction of the alkoxyamines (4 and 9) with either 4,6-dichloro-5-formamidopyrimidine (10) or 4,6-dichloro-2, 5-diformamidopyrimidine (11) in the presence of base gave the 6-alkoxyaminopyrimidines (12-15) in 60-80% yield ( Fig. 1 ). Cyclization to 6-chloropurines (16-19) was achieved in 63-94% yield with refluxing diethoxymethyl acetate. Upon reaction with ammonia in ethanol followed by treatment with trimethylsilyl bromide, displacement of the 6-chloro substituent, removal of N-formyl groups and de-esterification occurred, affording the adenine and 2,6-diaminopurine derivatives (20-23) in 20-40% overall yield. Reaction of the 6-chloropurine (17)with trimethylsilyl bromide, followed by hydrolysis gave in 51% yield the 2-amino-6-chloropurine derivative (24), which was converted with sodium methoxide to the 6-0-methylguanine (25) in 71% yield. Hydrolysis of (16) and (17) with 80% formic acid followed by de-esterification with trimethylsilyl bromide afforded the hypoxanthine and guanine derivatives (26) and (27) in 37% and 48% yield, respectively.
The branched chain adenine derivative (22) was also prepared by an alternative route involving reaction of 9-hydroxy-6-phthalimidopurine (28) under Mitsunobu conditions (Fig. 2) . The 9-alkoxypurine (29) was obtained in 80% yield and upon treatment with N-methylhydrazine followed by acid hydrolysis was converted to the adenine derivative (30) in 66% overall yield. De-esterification using trimethylsilyl bromide then afforded a mixture of the phosphonic acid (22) and its mono-ethyl ester (31) in 22% and 36% yield respectively. Reaction of the alcohol (8) with 2-[bis+butoxycarbonyl)amino]-9-hydroxy-6-methoxypurine (32) under Mitsunobu conditions (Fig. 3 ) gave the 9-alkoxypurine (33) in 59% yield. Upon acid hydrolysis and de-esterification with trimethylsilyl bromide, compound (33) was converted to the guanine derivative (34) in 31% overall yield. Treatment of (34) with dicyclohexylcarbodiimide provided the cyclic phosphonate (35) in 61% yield.
Biological evaluation
This new series of acyclonucleotides was evaluated in cell culture for activity against the herpesviruses (H8V-1 and inhibit DNA synthesis in uninfected cells (as measured by incorporation of tritiated thymidine) and would therefore be expected to inhibit MRC-5 cell proliferation. More interestingly, the replication of visna virus in sheep choroid plexus (SCP) cells is inhibited by all of these acyclonucleotides and several of them show extremely high potency and selectivity against this lentivirus. The 2-amino-6-substituted purines (21), (23), (24), (25), (27) a. Concentration of compound which inhibited by 50% the number of plaques (HSV-2, VZV and CMV) orCPE (HSV-1) in infected cells, or incorporation of f'H]TdR into uninfected cells. 
Diethyl2-hydroxyethoxymethylphosphonate (3)
To a solution of diethyl 2-acetoxyethoxymethylphosphonate (2) (Robins and Hatfield, 1982) (16 g, 63 mmol) in ethanol (150 ml) was added 0.5 M sodium ethoxide (12.2 mI). After standing at ambient temperature overnight, 1R-120H resin was added until pH 6.5 was reached. The solution was filtered immediately, the resin 9-[2-(phosphonomethoxy) 3000, 2950, 2920, 1795, 1745, 1735, 1430, 1380, 1250, 1190, 1165, 1130, 1030, 980, 880 (55ml) was added methylhydrazine (1.83 ml, 34.4 mmol). After stirring at ambient temperature for 2 h, the reaction mixture was filtered and evaporated to dryness. The residue was purified by chromatography on silica gel, eluting with dichloromethane-methanol (98:2) to give compound (4)as an oil (6g, 92%): IR (film) vmax3480, 3320, 2995, 2920, 1600, 1445, 1390, 1370, 1240, 1170 
DiethyI2-benzyloxy-1-(benzyloxymethylj ethoxymethylphosphonate (6)
Dry HCI gas was bubbled through an ice-cooled solution of 1,3-dibenzyloxypropan-2-01(5) (25 g, 0.092 mol) and paraformaldehyde (2.75 g, 0.092 mol) in dry dichloromethane (100 ml) for 1 h. The resulting solution was dried (MgS0 4) and evaporated to dryness to leave an oil. Triethyl phosphite (15.7 ml, 0.092 mol) was added and the resulting mixture was stirred and heated at 140°C for 16 h. The liquid obtained was dissolved in ethyl acetate and washed with sodium bicarbonate solution. The organic phase was washed with brine, dried (MgS0 4) and evaporated to give a mobile oil, which was purified by chromatography on silica gel, eluting with hexane-ethyl acetate (50: 50) to give compound (6)as a colourless, mobile oil (19.7g, 51%): IR (film) "max 3055,3020. 2900, 2860, 1490, 1470, 1450. 1390, 1305, 1255, 1095, 1050, 1030,970,820,770,735 
DiethyI2-hydroxy-1-(hydroxymethylj ethoxymethylphosphonate (7)
To a solution of compound (6) (15.5g, 36.7 mmol) in ethanol (200ml), containing methanolic HCI (1ml), was added 10% palladium carbon (Pd-C) (1.5g). The mixture was treated with hydrogen at atmospheric temperature and pressure for a total of 6 days. Filtration and evaporation of the solvent gave an oil which was chromatographed on silica gel, eluting with dichloromethane-methanol mixtures (95: 5, then 92: 8) to obtain the diol (7) (2.73g, 30%): IR (film) v max 3400, 2980, 2940, 2920, 1650, 1480, 1445, 1390, 1370, 1295, 1230, 1165, 1120, 1020, 980, 880, 820 and 780 crrr". 1H NMR [(CDshSOj 31.23 (6H, t, J = 7Hz, (OCH 2CHsh), 3.25-3.6 (5H, m, CH 2CHCH2), 3.94 (2H, d, J = 8.2 Hz, OCH2P), 4.0-4.2 (4H, m, (OCH 2CHs l2),4.56 (2H, br.s, D 20 exchangeable, 2 x OH); HRMS calculated for C 8H200 6P (MH+), 243.0998; found 243.0986.
Also isolated was the mono benzyl ether of (7) (3.65 g, 30%). IR (film)"max 3395, 2980, 2900, 2860, 1475, 1450, 1390, 1365, 1240, 1160, 1090, 1050, 1020, 970, 810, 775, 730 
DiethyI2-acetoxy-1-(hydroxymethylj ethoxymethylphosphonate (8)
To a solution of compound (7) (6.1g, 25.2 mmol) in dry THF (75ml) were added p-toluenesulphonic acid (250mg) and trirnethyl orthoacetate (4.45 rnl, 35 mmol). The reaction mixture was stirred at ambient temperature for 16 h, after which water (1ml) and 2 M HCI (5 drops) were added. After stirring for a further 30 min, the solution was evaporated and the residue purified by chromatography on silica gel, eluting with dichloromethane-methanol (97: 3) to give compound (8) (5.1g, 71%) as colourless mobile oil: IR (film) "max 3400, 2980, 2920, 2910, 1740, 1440, 1390, 1370, 1245, 1160, 1120, 1050, 1030, 970, 820 DiethyI2-acetoxy-1-(aminooxymethylj ethoxymethylphosphonate (9) (a) Diethyl azodicarboxylate (1.89ml, 12 mmol) was added to a solution of compound (8) (3.1 g, 10.9 mmol), triphenylphosphine (3.15g, 12 mmol) and N-hydroxyphthalimide (1.78g, 10.7 mmol) in dry THF (60mI). The reaction mixture was stirred at ambient temperature under an atmosphere of nitrogen for 16 h and then evaporated. The residue obtained was dissolved in diethyl ether and left at 4°C for 16 h. The crystals of triphenylphosphine oxide were removed by filtration and the filtrate was evaporated. The residue was purified by chromatography on silica gel, eluting with hexane-acetone (70: 30) to give diethyl 2-acetoxy-1-(N-phthalimido-oxymethyl)ethoxymethylphosphonate as a pale yellow oil (3.6g, 76%): IR (film) "max 3500, 3460, 2980, 2900, 1780, 1735, 1465, 1440, 1370, 1240, 1185, 1160, 1030, 1020, 970, 875, 820, 780 and 700 cm-1; 1H NMR (CDCl s) 31.33 (6H, 2 x t, J = 7Hz, (OCH 2CHs l2),2.09 (3H, s, COCHs),3.9-4.5 (11H, m, (OCH 2CHsh, OCH 2P. OCH 2CHCH2), 7.75-7.87 (4H, m, aromatic); HRMS calculated for C18H2SNOgP (MH+), 430.1269; found, 430.1275. Anal. (C18H24NOgP) C,H,N.
(b) To a solution of diethyl 2-acetoxy-1-(N-phthalimidooxymethyl)ethoxymethylphosphonate (1.0g, 2.33 mmol) in dry dichloromethane (20ml) was added methylhydrazine (0.125ml, 2.35 mmol) and the solution was stirred at ambient temperature for 10 min. The reaction mixture was filtered and the filtrate was evaporated. The residue obtained was purified by chromatography on silica gel, eluting with dichloromethane-methanol (98: 2) to give compound (9) as a colourless oil (0.59g, 86%): IR (film) "max 3460, 3320, 3240, 3170, 2995, 2910, 1740, 1595, 1445, 1390, 1370, 1240, 1165, 1115, 1050, 1025, 975, 820 
4-Chloro-6-[2-(diethoxyphosphorylmethoxy)ethoxyaminoj-5-formamidopyrimidine (12)
A mixture of 4,6-dichloro-5-formamidopyrimidine (10) (1.9g, 10 mmol), compound (4)(2.27g, 10 mmol) and triethylamine (2ml, 15 mmol) in dry 1,4-dioxane (50ml) was heated at 100°C for 4 h. After cooling to ambient temperature, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residual oil was purified by chromatography on silica gel, eluting with dichloromethane-methanol mixtures (98:2, then 95:5) to give compound (12) as an oil (2.7g, 70%): IR (film) "max 3200, 2995,1690,1640,1600.1570,1240,1165 
4-Chloro-6-[2-(diethoxyphosphorylmethoxy)ethoxyaminoj-2,5-diformamidopyrimidine (13)
A mixture of 4,6-dichloro-2,5-diformamidopyrimidine (11)(2.35g, 10 mmol), compound (4) (2.27g, 10 mmol) and diisopropylethylamine (3.48ml, 20 mmol) in diglyme (40ml) was heated at 100°C for 3 h. After cooling to ambient temperature, the solvent was removed and the residue purified by chromatography on silica gel, eluting with dichloromethane-methanol (97: 3) to give compound (13) 
6-[[S-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] amino]-4-chloro-5-formamidopyrimidine (14)
A mixture of 4,6-dichloro-5-formamidopyrimidine (10)(0.77g, 4.0 mmol), compound (9) (1.2g, 4.0 mmol) and triethylamine (0.82ml, 6 mmol) in dry 1A-dioxane (20ml) was heated at 100°Cfor 2 h. The reaction mixture was cooled, filtered, and the filtrate was evaporated to leave an oil which was purified by chromatography on silica gel, eluting with dichloromethane-methanol (97:3) to give compound (14) 
6-[[S-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] amino]-4-chloro-2,5-diformamido pyrimidine (15)
A mixture of 4,6-dichloro-2,5-diformamidopyrimidine (11) (0.475g, 2 mmol), compound (9) (0.60g, 2 mmol) and triethylamine (0.54ml, 4 mmol) in dl}t 1,4-dioxane (20ml) was heated at 120°C for 5h. The reaction mixture was cooled to ambient temperature, filtered, and the filtrate was evaporated to leave a yellow oil. The oil was purified by chromatography on silica gel, eluting with dichloromethane-methanol (97: 3) to give compound (15) 
6-Chloro-9-[2-(diethoxyphosphorylmethoxy)ethoxy] purine (16)
A solution of comound (12) (2.4g, 6.3 mmol) in diethoxymethyl acetate (10ml) was heated at 120°C for 45 min. After cooling to ambient temperature, the solvent was removed under reduced pressure. The residue was dissolved in methanol (15ml) and 35% ammonium hydroxide (1ml). After 15 min, the solvent was removed and the residue purified by chromatography on silica gel, eluting with dichloromethane-methanol (98:2) to give compound (16) as an oil (2.15g, 94%): IR (film) "max 3100, 3070, 2995, 1600, 1570, 1440, 1395, 1335, 1250, 1220, 1170, 1030, 930 and 640 
6-Chloro-9-[2-(diethoxyphosphorylmethoxy)ethoxy]-2formamidopurine (17)
A solution of compound (13) (2.8g, 6.6 mmol) in diethoxymethyl acetate (20ml) was heated at 120°C for 2h. After cooling to ambient temperature, excess solvent was removed, the residue 9-[2-(phosphonomethoxy)alkoxy]purines 235 was dissolved in methanol (20ml) and 35% ammonium hydroxide (6.5ml) and the solution stirred at ambient temperature for 1 h. The solvent was evaporated to leave an oil which was purified by chromatography on silica gel, eluting with dichloromethanemethanol (98: 2) to give compound (17)as a pale yellow oil (2.4g, 90%): IR (film) "max 3480,3120,2995 ,1710 ,1610 ,1580 ,1510 , 1440 ,1390 ,1330 ,1240 ,1050 ,1030 81.23 (6H,t, J = 7Hz, (OCH 2CH3 h ),3.87 (2H,d, J =' 8 Hz, OCH 2P), 3.87 (2H, m, NOCH 2CH20), 4.03 (4H, rn, (OCH 2CH 3 h ), 4.56 (2H, m, NOCH 2CH2), 8.75 (1H, s, H-8), 9.38 (1 H, br.s, CHO), 11.30 (1H, br.s, 0 20 exchangeable NHCHO); HRMS calculated for CI3H2oNs08PCI(MH+), 408.0840; found, 408.0827. Anal. (CI3HI9Ns06PCI.0.1 H20) C,H,N.
9-[S-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] -6-chloropurine (1B)
A solution of compound (14)(0.80g, 1.76 mmol) in diethoxymethyl acetate (5ml) was heated at 120°Cfor 2 h. After cooling to ambient temperature, the excess solvent was evaporated under reduced pressure. The residue obtained was dissolved in methanol (5ml) and 35% ammonium hydroxide (1 ml) and left at ambient temperature for 10 min. The solvent was removed under reduced pressure and the residue purified by chromatography on silica gel, eluting with dichloromethane-methanol (98:2) to give compound (18) as a yellow oil (0.68g, 88%): IR (film) "max 3080, 3050, 2990, 2900, 1740, 1640, 1590, 1565, 1435, 1390, 1370, 1330, 1240, 1160, 1120, 1040, 1025, 970, 930, 850, 820 
9-[S-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] -6-chloro-2-formamidopurine (19)
A solution of compound(15) (0.30g, 0.66 mmol) in diethoxymethyl acetate (5ml) was heated at 120°C for 3 h. After cooling to ambient temperature, excess solvent was removed under reduced pressure. The residue obtained was dissolved in methanol (2ml) and 35% ammonium hydroxide (0.5ml) and left at ambient temperature for 15 min. The solvent was removed under reduced pressure and the residue obtained purified by chromatography on silica gel, eluting with dichloromethane-methanol (97:3) to give compound (19) 
9-[2-(Phosphonomethoxy)ethoxy]adenine (20)
(a)A solution of compound (16) (1.45g, 4 mmol) in ethanol (20ml) saturated with ammonia gas was heated in a sealed steel vessel at 100°C for 2 h. The reaction mixture was cooled to ambient temperature, evaporated and the residual oil chromatographed on silica gel, eluting with dichloromethane-methanol (90: 10) to give recovered starting material (0.25g) and 9-[2-(diethoxyphosphorylmethoxy)ethoxyjadenine (0.94g, 82% -based on used starting materia!), m.p. 74-76°C (from acetone-ether): UV (EtOH) A max 260nm (E 13500); IR (KBr) "max 3308, 3146, 1669, 1646, 1600, 1538, 1466, 1416, 1320, 1301, 1232, 1206, 1164, 1129, 1066, 1053, 1039, 1009 (b) To a solution of 9-[2-(diethoxyphosphorylmethoxy)ethoxyj adenine (O.63g, 1.83 mmol) in dry dichloromethane (10m!) was added trlmethylsilylbromlde (1.45ml, 11 mmol) and the solution was stirred at ambient temperature for 2 h. The solvent was removed under reduced pressure and the residue co-evaporated with methanol (2 x 10ml) to give compound (20) (0.24g, 45%), m.p. 241-244°C (from aqueous methanol); UV (EtOH) A max 259nm (E 13500); IR (KBr) "max 3428, 3312, 3084, 1685, 1644, 1612, 1484, 1462, 1455, 1336, 1294, 1278, 1255, 1215, 1195, 1104, 1060, 1046, 1033, 955, 934 
2,6-Diamino-9-[2-(phosphonomethoxy)ethoxyjpurine (21)
(a) A solution of compound (17) (0.80g, 1.96 mmol) in ethanol (10ml) saturated with ammonia gas was heated in a sealed steel vessel at 110°C for 5.5 h. The reaction mixture was cooled to ambient temperature, evaporated and the residue chromategraphed on silica gel, eluting with dichloromethane-methanol (90: 10) to give 2,6-diamino-9-[2-(diethoxyphosphorylmethoxy) ethoxyjpurine (0.25g, 35%), m.p. 139-141°C (acetonitrile): UV (EtOH) A max (E 8200), 280 (E 10200) nm; IR (KBr) "max 3443, 3404, 3320, 3152, 2984, 2940, 1662, 1644, 1608, 1586, 1505, 1480, 1414, 1403, 1360, 1338, 1277, 1265, 1241, 1229, 1221, 1187, 1163, 1113, 1098, 1052, 1024, 978, 881, 842, 789, 769 (b) To a solution of 2,6-diamino-9-[2-(diethoxyphosphorylmethoxy)ethoxyjpurine (0.15g, 0.41 rnmol) in dry dichloromethane (3m!) and dry OMF (1ml) was added trimethylsilyl bromide (0.55 ml, 4.1 mmol) and the solution stirred at ambient temperature for 2 h. The solvent was removed under reduced pressure and the residue was dissolved in methanol. The solution was evaporated and the solid residue obtained triturated with methanol to give compound (21) (75mg, 59%), m.p. >300°C. IR (KBr) Vmax3369,3145,3138,3120, 1658 Vmax3369,3145,3138,3120, , 1617 Vmax3369,3145,3138,3120, , 1593 Vmax3369,3145,3138,3120, , 1532 Vmax3369,3145,3138,3120, , 1485 Vmax3369,3145,3138,3120, , 1455 Vmax3369,3145,3138,3120, ,1419 Vmax3369,3145,3138,3120, ,1405 Vmax3369,3145,3138,3120, ,1368 Vmax3369,3145,3138,3120, ,1285 Vmax3369,3145,3138,3120, ,1232 Vmax3369,3145,3138,3120, ,1163 1118 ,1059 (b) To a solution of compound (30) (90mg, 0.24 rnrnol) in dry dichloromethane (2.5m!) and dry OMF (0.5ml), was added trimethylsilyl bromide (0.19ml, 1.44 mmol) . After stirring at ambient temperature for 2 h, the solvent was evaporated and the residue co-evaporated with methanol (x2). The residue was chromatographed on reverse phase silica, eluting with water and then with 5% and 10% aqueous methanol to give compound (22) (17mg, 22%), m.p. 197-203°C: [UV (EtOH) Amax259nmj; IR (KBr) "max 3550-21 00 (br.), 1704, 1608, 1467, 1418, 1340, 1304, 1229, 1207, 1163, 1125, 1079, 925, 889, 778, 757 Also isolated was the monoethyl ester (31) (30mg, 36%), m.p. 90-95°C: IR (KBr) "max 3600-2200 (br.), 1692, 1647, 1602, 1472, 1413,1333,1296,1166,1128,1047,953,882,795,781 
2,6-Diamino-9-[3-hydroxy-2-(phosphonomethoxy)propoxy]purine (23)
A solution of compound (19) (0.16 g, 0.33 mmol) in ethanollc ammonia (5ml) was heated in a sealed vessel at 120°C for 5 h. The Solution was allowed to cool to ambient temperature and the solvent was removed under reduced pressure to leave a brown residue. The residue was purified by preparative TLC, eluting with dichloromethane-methanol (80: 20) to give 2,6-diamino-9-[2-(diethoxyphosphorylmethoxy)-3-hydroxypropoxyjpurine as a colourless gum (65 mg). The gum was dissolved in dry dimethylformam ide (OMF) (1ml) and trimethylsilyl bromide (0.3ml, 1.53 mmol) added. After 3h at ambient temperature, the solvent was removed under reduced pressure and the residue obtained was dissolved in 50% aqueous acetone. Evaporation of the solvent gave a solid which after crystallization from hot water, gave compound (23) 
2-Amino-6-chloro-9-[2-(phosphonomethoxy)ethoxy] purine (24)
To a solution of compound (17) (0.370g, 0.91 mmol) in dry OMF (5ml) was added trimethylsilyl bromide (1.3 ml, 9.6 mmol) and the solution was stirred at ambient temperature for 3h. The solvent was removed under reduced pressure and the residue co-evaporated with 50% aqueous acetone (xz). The solid residue obtained was crystallized from hot water to give compound (24) as a tan solid (0.15g, 51%), m.p. 19D-195°C: IR (KBr) "max3480, 3430, 3200, 3150, 2920, 1660, 1625, 1570, 1525, 1480, 1370, 1320, 1235, 1195, 1125, 1105, 1030, 995, 950, 920, 880 and 780 
2-Amino-6-methoxy-9-[2-(phosphonomethoxY)ethoxy] purine (25)
To a solution of compound (24) (0.10g, 0.31 mmol) in methanol (3ml) was added 30% sodium methoxide in methanol (0.59 rnl,3.1 mmol) and the reaction mixture was stirred at 50°C for 5h. The solution was cooled to ambient temperature, diluted with methanol (20ml) and Amberlite IR-120 (H+) resin added to obtain a solution of pH 2.5. The solution was filtered, the resin washed with 50% aqueous methanol (30ml) and the combined filtrates concentrated under reduced pressure. The residue was purified by reverse-phase silica column chromatography using water as eluant to give compound (25) -[2-(phosphonomethoxY) alkoxy]purines 237 ethoxy]hypoxanthine (26) (a) A solution of compound (16) (300mg, 0.82 mmol) in 80% formic acid (3ml) was heated at 80°C for 2h. After cooling to ambient temperature, the solution was evaporated and the residue was chromatographed on silica gel, eluting with dlchloromethane-methanol (98: 2 and then 90: 10) to give 9-[2-(diethoxyphosphorylmethoxy)ethoxyjhypoxanthine as a yellow solid (2,10mg, 73%), m.p. 121-124°C; UV(EtOH) Amax250 (E 9830) nm; IR (KBr) "max 3444. 3125, 3080, 3053, 2987, 2934, 2900, 2854, 2820, 1705, 1582, 1560, 1533, 1448, 1415, 1396, 1350, 1331, 1256, 1234, 1121, 1052, 1023, 978 (b) Trimethylsilyl bromide (0.32ml'-2.4 mmol) was added to a solution of 9-[2-(diethoxyphosphorylmethoxy)ethoxyjhypoxanthine (83 mg, 0.24 mmol) in dry OMF (2ml) at ambient temperature. After 16h, the solvent was evaporated and the residue was crystallized from acetone-water to give compound (26) as a white solid (35mg, 50%), m.p. 205-215°C; UV (EtOH)
A max 250 (E 11560),245 (E 11420) nm; IR (KBr) vmax 3429,3123, 3060,3012.2906,2887,1700,1570,1482, 1455, 1421, 1342, 1258,1168,1128,1111,1045,1033,1012,942,914 (27) (a)A solution of compound (17) (2.1 g, 5.1 mmol) in 80% aqueous formic acid (15 ml) was stirred and heated at 80°C for 1.5 h. After cooling to ambient temperature, the reaction mixture wasevaporated under reduced pressure, the residue dissolved in methanol (20ml) and 35% ammonium hydroxide (2ml) and left at ambient temperature for 1 h. The Solvent was evaporated and the residue was purified by chromatography on silica gel, eluting with dichloromethane-methanol, (90: 10) to give 9-[2-(diethoxyphosphorylmethoxy)ethoxyjguanine (1.5 g, 80%), m.p. 176-'178°C; UV (H 20) A max 253 (E 13300),275 (E 9050) nm; IR (KBr) "max 3334, 3156,1693,1646,1601,1590,1242,1163,1054,1025 and 970 crrr " (b) To a solution of 9-[2-(diethoxyphosphorylmethoxy)ethoxyj guanine (100mg, 0.28 mmol) in dry OMF (2ml) was added trimethylsilyl bromide (0.22 ml, 1.66 mmol). The reaction mixture was stirred for 16h at ambient temperature, evaporated and the residue obtained dissolved in methanol (5ml). After 5 min at ambient temperature, the methanol was removed by evaporation and the residue was co-evaporated with methanol (2 x 5 mI). The solid obtained was suspended in water and 35% ammonium hydroxide was added until the solution pH reached 9--10. The basic solution was added to Oowex 50W-X8 resin (OH-) and the resin was washed with water. Fractions containing UV absorbing material were combined and acidified with 2 MHCI to precipitate a solid. The precipitate was collected and triturated with methanol to give compound (27) as a white solid (50mg, 60%), m.p. 272-278°C; UV (EtOH) A m ax 254 (E 10800), 278 sh (E 6400) nm; IR (KBr)-max 3378,3161,1705 ,1649 ,1602 ,1459 and 1382 33.60 (2H, d, J = 8.25 Hz, OCH2P),3.77 (2H, m, CH 20CH 2P), 4.37 (2H, m, NOCH 2CH2), 6.63 (2H, br.s, 0 20 exchangeable NH2l, 7.92 (1H, s, 10.67 (1H, br.s, 0 20 exchangeable NH), br., P(OHh) . Anal. (C aH12Ns-OaP.0.5H20) C,H,N.
9-[3-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] -6-N-phthalimidopurine (29)
Oiethyl azodicarboxylate (O.4ml, 2.6 mmol) was added to a mixture of 9-hydroxy-6-N-phthalimidopurine (28) (0.61g, 2.17 mmol), compound (8) and triphenylphosphine (O.68g, 2.6 mmol) in dry THF (20ml) at O°C. A pale yellow solution was obtained within a few min and the reaction mixture was then stirred at ambient temperature for 2 h. The solvent was evaporated under reduced pressure and the residue obtained purified by chromatography on silica gel, eluting with hexane-acetone mixtures (3: 1, then 1 :3) to give compound (29) as a colourless oil (O.95g, 80%); IR (film) "max 3100,3060,2980 ,2910 ,1790 ,1740 ,1730 ,1600 , 1580 ,1465 ,1445 ,1405 ,1370 ,1330 ,1240 ,1160 ,1135 ,1020 31.23 (6H,t, J = 7 Hz, (OCH~CH3h), 2.05 (3H, s, COCH3), 3.95-4.45 (9H, m, OCH 2CH3h), OCH 2P, CHCH 20Ac), 4. m, NOCH 2), rn, aromatic), 9.04 (1H, s), 9.11 (1 H, s); FABMS (positive ion, thioglycerol) 548 (MH+, 100%).
9-[2-(Diethoxypbosphorylmethoxy)-3-hydroxypropoxy] adenine (30)
(a) To a solution of compound (29) (0.91g, 1.66 mmol) in dry dichloromethane (5ml) was added methylhydrazine (0.09ml, 1.83 mmol) and the solution was stirred at ambient temperature for 15 min. The reaction mixture was filtered, the white solid was washed with dichloromethane and the combined filtrates were evaporated. The residue obtained was purified by chromatography on silica gel, eluting with dichloromethane-methanol (95: 5) to give 9-[3-acetoxy-2-(diethoxyphosphorylmethoxy)propoxy]adenine as a colourless oil (O.58g, 83%): IR (film) "max 3330,3190,2990 , 2900 ,1740 ,1660 ,1640 ,1595 ,1470 ,1410 ,1370 ,1330 ,1295 , 1240 ,1050 ,1020 (b) A solution of 9-[3-acetoxy-2-(diethoxyphosphorylmethoxy) propoxy]adenine (O.58g,1.39 mmol) in ethanol (10ml) and 2 MHCI (1.5ml, 3.0 mmol) was heated under reflux for 16 h. The solution was cooled to ambient temperature and evaporated. The residue obtained was dissolved in ethanol and 35% ammonium hydroxide added to give a final solution of pH 8.5. The solvent was removed under reduced pressure and the residue obtained was chromatographed on silica gel, eluting with dichloromethanemethanol mixtures (95: 5, then 92: 8, and finally 90: 10) to give compound (30) as a pale yellow oil (0.42g, 80%). Spectroscopic and analytical data for this material were identical to those recorded for the sample of compound (30) prepared previously [see preparation of compound (22)].
9-[3-Acetoxy-2-(diethoxyphosphorylmethoxy)propoxy] -2-[bis-(t-butoxycarbonyljamino]-6-methoxypurine (33)
Oiethyl azodicarboxylate (0.49ml, 3.15 mmol) was added to a mixture of 2-[bis-(t-butoxycarbonyl)amino]-9-hydroxy-6methoxypurine (32) (1 g, 2.6 mmol) triphenylphosphine (O.28g, 3.15 mmol) and compound (8)(O.74g,2.6 mmol) in dryTHF (20ml) at O°C. The reaction mixture was stirred at ambient temperature for 3 h, the solvent was removed under reduced pressure and the residue obtained was chromatographed on silica gel, eluting with hexane-acetone mixtures (3: 1, 1: 1, and finally 1: 3) to give compound (33) as a colourless oil (1 g, 59%): IR (film) "max 2980, 2940, 1790, 1740, 1595, 1490, 1425, 1370, 1280, 1250, 1165, 1120, 1100, 1050, 970, 850 
9-[3-Hydroxy-2-(phosphonomethoxy)propoxy]guanine (34)
(a)A solution of compound (33)(2.8 g, 4.3 mmol) in ethanol (40ml) and 2M HCI (10ml) was heated under reflux for 5h. The solution was cooled and evaporated. The residue obtained was chromatographed on silica gel, eluting with dichloromethane-methanol (80: 20) to afford 9-[2-diethoxyphosphorylmethoxy)-3-hydroxypropoxy]guanine (O.8g, 47%), m.p. 12g-.:.133°C: IR (KBr) "max 3335, 3150, 2984, 2933, 1693, 1648, 1602, 1476, 1382, 1244, 1164, 1116, 1053, 1026 (b) To a solution of 9-[2-(diethoxyphosphorylmethoxy)-3hydroxypropoxy]guanine (60mg, 0.15 mmol) in dry OMF (1ml) was added frimethylsilyl bromide (0.5ml, 3.75 mmol). The solution was kept at ambient temperature for 3 h and the solution was then evaporated under reduced pressure. The residue obtained was dissolved in methanol and the solution was evaporated again to leave an off-white solid. Trituration with methanol gave compound (34) as a white solid (34mg, 66%), m.p. >300°C: IR (KBr) Vmax3385,3159, 1715 Vmax3385,3159, ,1645 Vmax3385,3159, ,1598 Vmax3385,3159, ,1384 Vmax3385,3159, ,1157 Vmax3385,3159, ,1109 Vmax3385,3159, ,1060 4, A solution of dicyclohexylcarbodiimide (0.323g, 1.57 mmol) in t-butanol (15ml) and DMF (2ml) was added dropwise over 30 min to a solution of compound (34)(0.105g, 0.31 mmol) and N,N-dicyclohexyl-4-morpholinocarboxamidine (0.092g, 0.31 mmol) in 50% aqueous-t-butanol (1 Oml).The reaction mixture was heated under reflux for 8h, allowed to cool to ambient temperature overnight and then filtered. The filtrate was evaporated to dryness, water added and the mixture filtered again. The filtrate was evaporated and the solid obtained was purified on DEAE-Sephadex (HCO s form), eluting with a linear gradient of aqueous triethylammonium bicarbonate (pH 7.5) from'O.05Mto 0.25M.The required component was found in the 0.15 Mfractions.
Relevant fractions were combined and evaporated, co-evaporating three times with ethanol-water (3: 1) to remove traces of triethylamine. The residue was converted into a sodium salt form by passing an aqueous solution through a column of Dowex 50W-X8 (Na") resin and eluting with water. Relevant fractions were combined and lyophilized to leave compound (35)as a white amorphous solid (58mg, 61%); UV (H20 ) Amax 253 (E 11600) nm; IR (KBr) "max3408, 3140, 2956, 1696, 1611, 1529, 1479, 1382, 1323,1239,1210,1176,1082; 1044,1012,961,820,792 
Materials and Experimental procedures: virology
Celfs and media
Human MRC-5 cells were obtained from the National Institute for Biological Standards and Control, Holly Hill, UK and grown in Eagle's minimum essential medium (MEM) containing 10% foetal calf serum (FCS). Sheep choroid plexus (SCP)cells wereobtained from Dr M. Dawson of the Central Veterinary Laboratories, Weybridge, UK and grown in Eagle's MEM with Hanks' salts and 10% FCS.
Viruses
HSV-1 (SC16) was obtained from Dr H.J. Field, University of Cambridge, UK and HSV-2 (MS) was purchased from the American Type Culture Collection (ATCC), Rockville, MD. Stocks of both were prepared in BHK-21 cells. VZV (Ellen) and CMV (AD169) were purchased from the ATCC and stocks grown up in MRC-5 cells, visna virus (strain K184) was obtained from Dr M. Dawson, Central Veterinary Laboratories, and stocks prepared in SCP cells.
Determination of antiviral effects in celf culture
Antiviral activity agains HSV-2, VZV, and CMV was determined using a plaque reduction. assay in human MRC-5 cells, as 9_[2_(phosphonomethoxy)alkoxyjpurines 239 describedpreviously .~ntiviral activity a~~i~st HSV-1 was determined usinga cytopathic effect (CPE)Inhibition assay. MRC-5 cells in Eagle'sminimal essential medium (MEM) containing 5% newborn calf serum (NC,S) were in.fe?t~d in suspension with HSV-1 with an approxl.mate mu~tlpliclty of infection (MOl)of 0.1. Infected cells were~Ispensed Into ml~ro titre wells containing an equal volume of tissue culture medium (Eagle's MEMl5% NCS)containingvarying concent~atio~s of test compound.After 3 days, infectedcell cultures were fixe? In formal saline stained with carbolfuschin and the concentration of test comp~und reducing virus induce~CP.E by 50% (I.C so) determined. Antiviral activity against visna virus was determined usinga CPEinhibition assay.SCPcells were plated into~icrotitre wellsuntil monolayers were established.Cells were then Infected with visna virus (approximately 3 tissue culture infection doses per well) and incubated with varying concentrations of test compounds for 12-14 days in maintenance medium (Eagle's MEM with Hanks' salts containing 0.5% FCS). Monolayers were then fixed with formal saline, virus-induced CPE scored microscopically and the minimum concentration of compound giving complete protection (MIG) determined.
Determination of drug toxicity in proliferating celfs
The effect of compounds on the growth of uninfected cells was investigated by a fH]thymidine incorporation assay. Cells were plated into microtitre wells (1 x 10 4 cells per well) in the presence of varying concentrations of compound an~allowed t~gr~~for 48h. Active cell replication was then determined by their ability to incorporate [6-3H]thymidine (0.5 fLCi/well) into cellular.~NA during a 5h pulse-labelling experiment. Cells were trypsinized and cellular DNA collected onto glass fibre filters using an LKB cell harvester. Levels of thymidine incorporation were then determined by scintillation counting and the 50% inhibitory concentration (lC so) of compounds determined. In u;treated controls between 15000 and 20000 c.p.m./well of H were typically incorporated.
